Multiple Myeloma Clinical Trials
Find clinical trials for multiple myeloma. Search for multiple myeloma clinical trials in different cities and states across the United States.
Elotuzumab, CC-92480, DexamethasoneElotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
Sponsor:
Abdullah Khan
Location:
Code:
NCT05981209
Conditions
Recurrent Multiple Myeloma
Refractory Multiple Myeloma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Bone Marrow Aspiration
Bone Marrow Biopsy
Computed Tomography
Dexamethasone
RRMMMMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
Sponsor:
Multiple Myeloma Research Consortium
Location:
Code:
NCT06171685
Conditions
Relapse Multiple Myeloma
Refractory Multiple Myeloma
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Teclistamab Monotherapy
Teclistamab
ABBV-383A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma
Sponsor:
TeneoOne Inc.
Location:
Code:
NCT05650632
Conditions
Multiple Myeloma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
ABBV-383
ElranatamabElranatamab in R/R Multiple Myeloma
Sponsor:
Massachusetts General Hospital
Location:
Code:
NCT06138275
Conditions
Refractory Multiple Myeloma
Relapse Multiple Myeloma
Multiple Myeloma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Elranatamab
64Cu-LLP2A64Cu-LLP2A for Imaging Hematologic Malignancies
Sponsor:
Washington University School of Medicine
Location:
Code:
NCT06636175
Conditions
Multiple Myeloma
Low-Grade Lymphoma
Follicular Lymphoma
Marginal Zone Lymphoma
Lymphoplasmacytic Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Accepted
Interventions
64Cu-LLP2A
PET/CT
MMSET InhibitorA Study of an MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma
Sponsor:
K36 Therapeutics, Inc.
Location:
Code:
NCT05651932
Conditions
Multiple Myeloma
Myeloma
Myeloma Multiple
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Cohort A1 & A2
Cohort C1 & C2
Cohort D
Teclistamab & DaratumumabTeclistamab or Talquetamab in Combination with Daratumumab for High-Risk Smoldering Myeloma (REVIVE Study)
Sponsor:
Carl Ola Landgren, MD, PhD
Location:
Code:
NCT06100237
Conditions
Multiple Myeloma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Teclistamab
Talquetamab
Daratumumab SC
JNJ-87562761A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
Sponsor:
Janssen Research & Development, LLC
Location:
Code:
NCT06604715
Conditions
Relapsed or Refractory Multiple Myeloma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
JNJ-87562761
Elotuzumab, Daratumumab, Iberdomide, DexamethasoneElotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
Sponsor:
Mayo Clinic
Location:
Code:
NCT06785415
Conditions
Recurrent Multiple Myeloma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Bone Marrow Aspiration
Bone Marrow Biopsy
Bone Scan
Chest Radiography
Computed Tomography
Carfilzomib, Lenalidomide, Dexamethasone, Belantamab MafodotinStudy of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
Sponsor:
Wake Forest University Health Sciences
Location:
Code:
NCT04822337
Conditions
Multiple Myeloma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin